ClinicalTrials.gg
Status unknownNCT04976283Updated Mar 18, 2022

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

A Phase 4 interventional study of Pioglitazone and Empagliflozin in Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis and NAFLD, sponsored by Getz Pharma. Status unknown at 1 site in Pakistan. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-18.

Sponsored by Getz Pharma · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Planned enrollment
52nd of 122
123 · median 103
Started
2021
with 3 others
Phase 4
57 of 122
4 open now
Registered
110th of 122
by date

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 52nd largest by planned enrollment, is one of 4 that started in 2021, is one of 57 in phase 4, and was the 110th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This randomized clinical trial aims to compare the effect of the pioglitazone and SGLT2 inhibitor combination on liver fat mass, as compared to either drug used alone, with or without background medical therapy of metformin and/or DDP4 inhibitors.

Read the detailed description

To compare the effect of pioglitazone with or without Metformin and/or DPP4 inhibitor (no SGLT2 inhibitor) on improvement of NAFLD parameters, versus

The effect of SGLT inhibitor with or without metformin and/or DPP4 inhibitor (no pioglitazone) on NAFLD parameters and versus

Pioglitazone with or without metformin and/or DPP4 inhibitor, plus empagliflozin on improvement of NAFLD parameters.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • NASH - Nonalcoholic Steatohepatitis
  • NAFLD
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient who give voluntarily
  • Type 2 diabetic patient having age from 18 years to 60 years
  • ≥ 7.0 %
  • Diabetes diagnosis of ≤ 5 years (longer duration more likely to be associated with use of multiple drug regimens for glycemic control which may affect liver fat mass)
  • Either treatment naïve or on metformin alone or metformin/DPP4i combination
  • Absolute weight \< 100kg; \< 45 (fibro scan machine cannot accommodate heavier individuals)
  • Documented hepatosteatosis (If the fibroscan reveals S1 (mild fatty liver: 11-33% fatty liver) to S3 (severe fatty liver: > 67% fatty liver) liver fat

Exclusion criteria

Exclusion Criteria:

  • ≥ 9% and/or blood sugar > 250mg/dl
  • History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requiring frequent dose adjustment, or Cushings syndrome)
  • History of anti-obesity medication use within 3 months of consent for study enrollment or weight loss procedure(bariatric surgery) within same duration
  • History of use of SGLT 2 inhibitors, glitazones, Glucagon-like peptide (GLP) 1 agonists 3 months prior to study enrollment as they influence liver fat
  • History of use of insulin/sulphonylurea 3 months prior to study enrollment owing to weight gain and potential increase in liver fat conferred by these agents
  • History of vitamin E use (400mg twice daily) within 3 months of study enrollment
  • Drug induced liver disease or active substance abuse (cannabonnoid-derived substances like heroin, cocaine, amphetamines) based on history and/or laboratory tests
  • Drugs known to be associated with hepatic steatosis like , traditional homeopathic medication (likely to contain steroids), methotrexate, valproate, tamoxifen, amiodarone.
  • Alcohol use (History of alcoholism or a greater than recommended alcohol intake (> 21 standard drinks on average per week in men and > 14 standard drinks on average per week in women)
  • Severe hepatic impairment ( levels > 3 times upper limit normal)
  • /C hepatitis (based on positive Hepatitis B surface antigen, Anti antibodies positive
  • hepatitis (in case of females), based on positive Anti-nuclear Antibody (ANA) (homogenous, high titre)
  • Positive ( HIV) test as this could influence liver functions
  • Pregnant or lactating women/ plans for pregnancy over proceeding 13 months
  • Obstructive liver disease on the basis of laboratory and imaging studies
  • Chronic renal failure, or (GFR) \< 30 mls/minute (as estimated by the MDRD equation)
  • Chronic heart failure, history of acute coronary artery disease or cerebrovascular accident within 3 months of consent for study enrollment, based on history and/or cardiac imaging
  • History of recurrent Urinary Tract Infections (UTI's) or mycotic infections
  • Presence of ketones on Urine Analysis
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Active comparator
    Pioglitazone

    The starting dose would be 15mg/day for pioglitazone and 500 to 1500mg per day for metformin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.

    Drug: Pioglitazone

  • Active comparator
    Empagliflozin

    The starting dose would be 500-1500mg/day of metformin, plus 5/10/12.5mg empagliflozin (depending on blood glucose levels). Starting dose for DPP4 inhibitors would be 50 to 100mg daily.

    Drug: Empagliflozin

  • Active comparator
    Pioglitazone + Empagliflozin

    The starting dose would be 15mg/day for pioglitazone and 500 to1500mg per day for metformin and 5/10/12.5mg/25mg/day empagliflozin and 50 to 100mg daily for DPP4 inhibitors depending on blood sugar levels.

    Drug: Pioglitazone + Empagliflozin

Interventions

  • Pioglitazone with (or without) metformin and/or DPP4 inhibitor (no SGLT2 inhibitor). The maximum dose for metformin would be 2.5 g/day, while for pioglitazone would be 45mg/day. The maximum dose for DPP4 inhibitor would be 100mg/day.

    Also known as: Zolid

  • Empagliflozin with (or without) metformin and/or DPP4 inhibitor (no pioglitazone). The maximum dose for metformin would be 2.5g/day, while for empagliflozin would be 25mg/day depending on follow up blood sugar levels and tolerability. The maximum dose 100mg daily.

    Also known as: Diampa

  • DrugPioglitazone + Empagliflozin

    Drug pages: Pioglitazone · Empagliflozin

    Pioglitazone with (or without) metformin and/or DPP4 inhibitor, plus empagliflozin. The maximum dose for metformin would be 2.5g/day; for pioglitazone would be 45mg/day and 25mg/day for empagliflozin, and 100mg daily for DPP4 inhibitors (depending on follow up blood sugar levels and tolerability).

    Also known as: Zolid + Diampa

06

What researchers measure

Primary outcomes

  1. Change in radiologic liver parameters

    Number of participants reported change in liver fat content from baseline, as quantified by fibroscan

    Time frame: 12 months

Secondary outcomes

  1. Change in liver enzymes

    Number of participants reported change in liver enzymes levels including ALT, AST and GGT

    Time frame: 12 months

  2. Change in Fibrosis-4 (FIB-4) Score and NAFLD Fibrosis Score

    Number of participants reported change in FIB-4 Score and NAFLD Fibrosis Score. Fibrosis-4 scores range from 0 to 4, where \<1.45 indicates absence of cirrhosis; score between 1.45 - 3.25 are deemed inconclusive and score \>3.25 indicates cirrhosis.

    Time frame: 12 months

  3. Change in body weight

    Number of participants reported change in body weight from baseline (treat to target response of at least 5% of baseline at 6 months, 10% baseline over 12 months).

    Time frame: 12 months

  4. Change in waist circumference (WC)

    Number of participants reported change in waist circumference (WC)

    Time frame: 12 months

  5. Change in liver fat mass with total body fat (TBF)

    Comparison of baseline and end of treatment liver fat mass with total body fat (TBF) using a Body Composition Monitor

    Time frame: 12 months

  6. Change in HbA1C levels (< 7.0%)

    Number of participants reported change in HbA1C levels from baseline to end of treatment

    Time frame: 12 months

  7. Change in Fasting Blood Sugar (FBS)

    Number of participants reported change in Fasting Blood Sugar (FBS) from baseline to end of treatment

    Time frame: 12 months

  8. Change in Lipid profile

    Number of participants reported change in Fasting triglycerides (TG), Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) from baseline to end of treatment

    Time frame: 12 months

Other outcomes

  1. Change in Urine Albumin to Creatinine Ratio (UACR)

    Number of participants reported change in Urine Albumin to Creatinine Ratio (UACR) from baseline to end of treatment

    Time frame: 12 months

  2. Change in Systolic and Diastolic blood pressure

    Number of participants reported change in Systolic and Diastolic blood pressure from baseline to end of treatment

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Aga Khan University Hospital
    Karachi, Sindh 74800, Pakistan
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for May 2023, 20 months after the start.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's planned 20 months is close to that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2021
First posted
Jul 26, 2021
StartActual
Sep 15, 2021
Primary completionEst.
May 15, 2023
CompletionEst.
Nov 15, 2023
Last update
Mar 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04976283
Lead sponsor
Getz Pharma
Responsible party
Dr. Najmul Islam (Professor Endocrinology, Diabetes, Aga Khan University) — Principal investigator
First posted
Jul 26, 2021
Start date
Sep 15, 2021
Primary completion
May 15, 2023 (estimated)
Completion
Nov 15, 2023 (estimated)
Last update
Mar 18, 2022

Study contacts

Azra Rizwan, FCPS
Contact
azra.rizwan@aku.edu
+923212655271

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Empagliflozin

Start the discussion